Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 4 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 4.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 liquidated — weigh against the wins.
1 vehicle on file, newest listing first
none appears on more than one
James Yervant Shekerdemian, born in April 1966, is a British financial services executive and director who currently serves on the board of directors of Collective Acquisition Corp. II (CAII), a special purpose acquisition company listed on Nasdaq. He was appointed to the board at the commencement of the company's listing and holds an indirect interest in 50,000 founder shares through his membership interests in the SPAC's sponsor, Collective Acquisition Sponsor II. The SPAC completed a $220 million initial public offering with Clear Street LLC acting as sole book-running manager and Reed Smith LLP serving as legal counsel. The board also includes Rear Admiral (Ret.) Matthew Burns and Lieutenant General (Ret.) Francis Beaudette, the latter of whom was appointed Chairman. Shekerdemian consented to be named as a director nominee in the company's SEC registration filings. The company is headquartered at 1000 Bricknell Avenue, Suite 715, PMB 5110, Miami, though Shekerdemian himself resides in England.
Shekerdemian's professional career has been centered in the prime brokerage and alternative investment solutions space. He served as Head of Origination and Structuring at Newedge, a leading global futures commission merchant and prime broker for liquid strategies, where he was a key spokesperson for the firm's alternative investment solutions business. In that role, he emphasized Newedge's agency model—distinguished by the absence of a proprietary trading desk—as a core driver of the firm's growth and its appeal to hedge fund managers and institutional investors alike. He highlighted Newedge's advisory approach, working closely with both investors and underlying managers to structure tailored solutions, including managed futures products within UCITS frameworks and U.S. mutual fund structures. His LinkedIn profile further describes his expertise in Global Prime Services, hedge funds, C-Suite relationship management, and business growth, with a title of Chief Commercial Officer (CCO), and an association with a School of Global Management in the United Kingdom.
In addition to his SPAC board role, Shekerdemian has held a number of directorships at UK companies registered with Companies House. He was appointed a director of The Clearing Partnership Ltd (company number 12936468) on 7 October 2020, a company that has since been dissolved. He was also a director of SVT Ventures Ltd (company number 12375110), appointed on 23 December 2019, which has also been dissolved. Earlier, he served as a director of 28 Sheen Road Management Company Limited (company number 03161650) from 4 April 2011 until his resignation on 7 August 2025, and as a director of Parsons House Residents Association Limited (company number 02162448) from 27 June 2001 until his resignation on 14 July 2024. All four appointments list his nationality as British and his country of residence as England, with a correspondence address at 29 Wolsey Road, East Molesey, Surrey, KT8 9EN.
Shekerdemian appears to be part of a prominent family with significant ties across finance, venture capital, and medicine. Nicholas Shekerdemian, a founding partner of The Venture Collective (TVC), an early-stage venture firm, and a Thiel Fellow, is likely his son; Nicholas co-founded TVC with Gina Shekerdemian (née Kirsch), a former BlackRock director and Forbes 30 Under 30 honoree. Lara Shekerdemian serves as Pediatrician-in-Chief at Texas Children's Hospital and holds the Ralph D. Feigin Endowed Chair as Professor of Pediatrics at Baylor College of Medicine, and Krikor Shekerdemian (1931–2021), a Cyprus-born neurologist and author, may also be a family member. These connections suggest a family with deep roots across global finance, healthcare, and entrepreneurship.
This record is keyed to SEC CIK 0002126505 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 5 institutional-holder rows on these vehicles, under 5 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.